Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of HBB Gene Correction in iHSCs for Beta-Thalassemia
NCT03728322Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- CRISPR-Cas9, Gene Silencing, Cell Therapies
01
Overview
Phase 1, open-label trial of HBB HSC-01 in beta thalassemia, sponsored by Allife Medical Science and Technology. Primary endpoint: Occurrence of treatment related adverse events at 1 year. Status: unknown.
02
Drugs
HBB HSC-01
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT03728322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728322.